Table 3.
Univariate Logistic Regression Results for Risk Factors Developing Thrombocytopenia
| Characteristic | Patients with Thrombocytopenia (n = 66) | Patients without Thrombocytopenia (n = 93) | P-value |
|---|---|---|---|
| Demographic analysis | |||
| Age (median, IQR) | 62 (48.5–72) | 61 (47.5–74) | 0.525b |
| Sex (male), n (%) | 43 (56.5) | 64 (68.8) | 0.911c |
| Medication days (median, IQR) | 6 (4–10) | 6 (3–10) | 0.442b |
| Length of hospital stay (median, IQR) | 14 (6–25) | 14 (7–24) | 0.879b |
| Duration of linezolid therapy (median, IQR) | 12 (8.5–17) | 6 (3–10) | 0.001c |
| ICU admission, n (%) | 36 (54.5) | 48 (51.6) | 0.972c |
| Comorbidities, n (%) | |||
| Renal insufficiency | 58 (87.9) | 93 (57.0) | 0.049c |
| Liver disease | 65 (98.5) | 92 (98.9) | 0.936c |
| Hypoproteinemia | 31 (47.0) | 33 (35.5) | 0.186c |
| MODS | 32 (48.5) | 43 (46.2) | 0.638c |
| Invasive procedure, n (%) | |||
| CRRT | 48 (72.7) | 39 (41.9) | 0.004c |
| Laboratory values | |||
| The difference of MPV, fL (median, IQR) | −0.08 (−1.2–0.9) | −0.5 (−1.5–0.3) | 0.051b |
| The difference of PLCR, (median, IQR) | 0.9 (−5.1–6.2) | −3.8 (−8.6–2.4) | 0.002b |
| Baseline PLT counts, ×109/L (median, IQR) | 105.6 (68.8–153.2) | 138.5 (50.1–212) | 0.019b |
| Baseline RBC, ×1012/L (median, IQR) | 2.9 (2.6–3.8) | 3.5 (2.9–3.9) | 0.005b |
| Baseline ALB, g/L (median, IQR) | 27.5 ±6.4 | 28.2± 4.9 | 0.315a |
| Baseline CREA, μmol/L (median, IQR) | 145 (62.1–293.5) | 108.6 (43–221) | 0.005b |
| Baseline BUN, mmol/L (median, IQR) | 11.3 (7.2–21.3) | 10.2 (5.8–16.3) | 0.285b |
| Baseline ALT, U/L (median, IQR) | 22.1 (13.9–52.6) | 38 (21.5–93.2) | 0.003b |
| Baseline AST, U/L (median, IQR) | 53.5 (21–100.2) | 46 (25–109) | 0.856b |
| Baseline ALP, U/L (median, IQR) | 99.5 (55.1–144.2) | 97 (65–157.9) | 0.527b |
| Baseline total bilirubin, μmol/L (median, IQR) | 21.3 (8.2–49.3) | 19.8 (11–45.6) | 0.956b |
| Co-medications, n (%) | |||
| Proton pump inhibitor | 45 (68.2) | 72 (77.4) | 0.631c |
| Amiodarone | 18 (27.2) | 9 (9.6) | 0.066c |
| Aspirin | 8 (12.2) | 10 (10.7) | 0.831c |
| Calcium antagonist | 9 (13.6) | 12 (12.9) | 0.572c |
| Parecoxib | 21 (31.8) | 11 (11.8) | 0.008c |
| Caspofungin | 26 (39.4) | 24 (25.8) | 0.018c |
| Levofloxacin | 8 (12.1) | 13 (13.9) | 0.539c |
| Meropenem | 37 (56.1) | 42 (45.2) | 0.817c |
| Glucocorticoids | 53 (80.3) | 65 (70.0) | 0.136c |
| Hospitalized death, n (%) | 13 (19.7) | 8 (8.6) | 0.003c |
Notes: aIndependent t test. bMann–Whitney U-test. cPearson’s Chi-squared test.
Abbreviations: MODS, multiple organ dysfunction syndrome; CRRT, continuous renal replacement therapy; the difference of MPV, the difference between mean platelet volume of starting and stopping linezolid; the difference of PLCR, the difference between platelet large cell ratio of starting and stopping linezolid; PLT, platelet; RBC, red blood cells; ALB, albumin; CREA, creatinine; BUN, blood urea nitrogen; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; IQR, interquartile range.